Quinazoline derivatives

Details Quinazoline derivatives Quinazoline derivatives

1990-12-14

1993-11-23

Shah, Mukund J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

5142325, 5142345, 544116, 544284, A61K 31505, C07D40106, C07D41314

Patent

active

052644383

ABSTRACT:
Compounds of the formula: ##STR1## are described wherein R.sup.1, R.sup.2, R.sup.3 and A are described in the claims. These compounds show significant dopamine receptor agonist activity.

REFERENCES:
patent: 3274194 (1966-09-01), Hayao
patent: 4684654 (1987-08-01), Wright, Jr. et al.
Chemical Abstracts, vol. 111, No. 21, Nov. 20, 1989, Columbus, Ohio, USA Cohen et al "Lack of a difference between ketanserin and ritanserin in Central vs. peripheral serotonin receptor antagonism" p. 70, Column 2, abstract No. 187 437y & Life Sci. 1989, 45(13), 1185-9.
Chemical Abstracts, vol. 110, No. 13, Mar. 27, 1989, Columbus, Ohio, USA S. Heptinstall, J. Bevan "How can we inhibit 5-HT-in-duced platelet aggregation and why should we bother?" p. 46, column 1, abstract No. 107 881e & Folia Haematol. (Leipzig) 1988, 115(4), 475-8.
Chemical Abstracts, vol. 101, No. 15, Oct. 8, 1984, Columbus, Ohio, USA A. Nevelsteen et al. "Restoration of post-thrombotic peripheral collateral circulation in the cat by ketanserin, a selective 5-HT2-receptor antagonist" p. 38, column 1, abstract-No. 122 772c & Arch Int. Pharmacodyn. Ther. 1984, 270(2), 268-79.

Affiliated with

Also associated with

Rating

Quinazoline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinazoline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1849085